Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.49 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.44 |
| ▸ | CALCR | P30988 | 7/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641591 | 0.89 | KEAP1 (0.49) | KEAP1CALCRLPTPN1RAMP3CALCR | |
| SCHEMBL29827592 | 0.84 | RAMP3 (0.53) | KEAP1PTPN1RAMP3CALCR | |
| SCHEMBL29827555 | 0.83 | KEAP1 (0.52) | KEAP1PTPN1RAMP3CALCR | |
| SCHEMBL9058995 | 0.83 | RAMP3 (0.56) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL9058997 | 0.83 | RAMP3 (0.56) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL30495783 | 0.82 | EP300 (0.48) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL30242243 | 0.82 | CXCR4 (0.53) | KEAP1RAMP3CALCROPRM1OPRD1 | |
| SCHEMBL30906410 | 0.82 | CALCRL (0.48) | KEAP1CALCRLRAMP3CALCR | |
| SCHEMBL31031606 | 0.81 | KEAP1 (0.43) | KEAP1CALCRLRAMP1OPRM1OPRD1 | |
| SCHEMBL31151696 | 0.81 | F2 (0.46) | KEAP1RAMP3CALCROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409709-A1 | LABYRINTHIN-BASED PEPTIDES FOR CANCER IMMUNOTHERAPIES AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS USA LTD (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220089719-A1 | CONSTRUCTS TARGETING LABYRINTHIN OR A PORTION THEREOF AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS (USA) LIMITED (US) | 2022-03-24 | — | — | US | disclosed |